Browse the corpus

Cephalexin is an antibiotic approved by the U.S. Food and Drug Administration (FDA) in 1970 and is classified as a first-generation cephalosporin. This drug is widely used in outpatient and inpatient healthcare settings due to its favorable safety and efficacy profile. Cephalexin is commonly utilized in the treatment of urinary tract infections, respiratory infections, otitis media, bone infections caused by Staphylococcus aureus or Proteus mirabilis, and skin and soft tissue infections primarily caused by S aureus or Streptococcus pyogenes. Cephalexin is administered prophylactically to minimize the risk of surgical site infections and other bacterial infections. Both streptococcal and staphylococcal species can cause these infections. This comprehensive activity provides an overview of the indications, mechanism of action, contraindications, and adverse effects of cephalexin, enabling the interprofessional healthcare team to utilize it appropriately in patient care. Objectives: Differentiate cephalexin from other antibiotics regarding the mechanism of action, the spectrum of activity, and potential indications to make informed treatment decisions when considering alternative therapies. Screen patients for contraindications to cephalexin, such as known hypersensitivity to cephalexin or other cephalosporins, and evaluate the risk of potential drug interactions. Implement appropriate dosing regimens based on the patient's age, weight, renal function, and severity of infection, ensuring accurate and safe administration of cephalexin. Communicate effectively with patients about cephalexin therapy, explaining the medication's purpose, potential benefits, and possible risks and adverse effects. Access free multiple choice questions on this topic.

Cephalexin is associated with a relatively low incidence of adverse effects in patients when the drug is administered correctly and safely. However, in cases of toxicity or overdose, adverse effects may include soreness of the oral cavity, pruritus of pregnancy, and gastrointestinal symptoms such as nausea, vomiting, epigastric distress, diarrhea, and hematuria.[1] Furthermore, there have been only a few sporadic documented cases of cephalexin leading to fatal episodes of Stevens-Johnson syndrome and toxic epidermal necrolysis.[18] In the event of an overdose, it is advisable to implement general supportive measures. However, the effectiveness of interventions such as charcoal hemoperfusion, forced diuresis, peritoneal dialysis, and hemodialysis in treating cephalexin overdose has not been established yet. To obtain the most up-to-date protocol for managing cephalexin overdose, it is recommended to contact the local drug poison center.

Interprofessional healthcare team members must be aware of the possibility of bacterial resistance to cephalexin. When cephalexin is administered to a patient with an infection that exhibits resistance to the drug, it poses a risk of subjecting the patient to potential adverse effects without effectively treating the infection. This can hinder effective infection management and increase the likelihood of developing antibiotic resistance. Healthcare teams must carefully consider the potential for drug-induced allergic reactions when administering cephalexin. The most common manifestations of such reactions with cephalexin are urticaria and maculopapular exanthema.[18] Nurses should inform patients of the possible adverse reactions associated with cephalexin and guide how to manage them. In cases of uncertainty, patients should be advised to contact their clinicians. Pharmacists should conduct medication reconciliation to ensure accurate dosing and the absence of potential drug interactions. Both nurses and pharmacists can offer patients valuable medication counseling to minimize the risks associated with cephalexin administration. Other significant and potentially life-threatening complications associated with cephalexin are Stevens-Johnson syndrome and toxic epidermal necrolysis. Although these complications are infrequent, healthcare providers must recognize the presenting symptoms, which typically include an extensive erythematous rash followed by widespread epidermal sloughing. In Stevens-Johnson syndrome and toxic epidermal necrolysis, the drug reaction can manifest as late as 1 to 3 weeks after the drug initiation. However, it is essential to note that these drug reactions can occur sooner than 1 to 3 weeks, presenting as conjunctivitis or lesions on mucosal membranes. Stevens-Johnson syndrome may also present with flu-like symptoms, including cough, arthralgias, myalgias, and fever. These symptoms can subsequently progress to extensive ulcerations on various body surfaces and multisystem organ failure, potentially resulting in death. Immediate discontinuation of cephalexin administration is paramount to prevent further progression and complications.[18]

Other significant and potentially life-threatening complications associated with cephalexin are Stevens-Johnson syndrome and toxic epidermal necrolysis. Although these complications are infrequent, healthcare providers must recognize the presenting symptoms, which typically include an extensive erythematous rash followed by widespread epidermal sloughing. In Stevens-Johnson syndrome and toxic epidermal necrolysis, the drug reaction can manifest as late as 1 to 3 weeks after the drug initiation. However, it is essential to note that these drug reactions can occur sooner than 1 to 3 weeks, presenting as conjunctivitis or lesions on mucosal membranes. Stevens-Johnson syndrome may also present with flu-like symptoms, including cough, arthralgias, myalgias, and fever. These symptoms can subsequently progress to extensive ulcerations on various body surfaces and multisystem organ failure, potentially resulting in death. Immediate discontinuation of cephalexin administration is paramount to prevent further progression and complications.[18] By collaborating and developing a collective understanding of identifying adverse drug reactions to cephalexin, the clinical team can effectively intervene and discontinue drug administration before severe complications arise. This necessitates open communication channels and shared decision-making capabilities among all interprofessional team members. Educating healthcare professionals on these matters fosters an environment that prioritizes patient safety and delivers high-quality care. The interprofessional management of cephalexin therapy, with the involvement of physicians, advanced practice practitioners, nursing staff, and pharmacists operating as a cohesive healthcare administration unit, will contribute to improved patient outcomes.